 Imidazoles
"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in UAMS Profiles by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 3 | 1 | 4 | | 2020 | 4 | 1 | 5 | | 2019 | 3 | 1 | 4 | | 2018 | 1 | 0 | 1 | | 2017 | 2 | 1 | 3 | | 2016 | 3 | 0 | 3 | | 2015 | 2 | 4 | 6 | | 2014 | 2 | 1 | 3 | | 2013 | 7 | 1 | 8 | | 2012 | 8 | 2 | 10 | | 2011 | 6 | 4 | 10 | | 2010 | 4 | 0 | 4 | | 2009 | 2 | 2 | 4 | | 2008 | 1 | 1 | 2 | | 2007 | 2 | 2 | 4 | | 2006 | 2 | 2 | 4 | | 2005 | 2 | 1 | 3 | | 2004 | 0 | 2 | 2 | | 2003 | 1 | 2 | 3 | | 2002 | 0 | 2 | 2 | | 2000 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 1998 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1992 | 1 | 0 | 1 | | 1990 | 2 | 1 | 3 | | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles over the past ten years.
-
Fouda AY, Ahmed HA, Pillai B, Kozak A, Hardigan T, Ergul A, Fagan SC, Ishrat T. Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke. Neurochem Int. 2022 09; 158:105375.
-
Tambiah JRS, Simsek I, Swearingen CJ, Kennedy S, Cole BJ, McAlindon TE, Yazici Y. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. Am J Sports Med. 2022 Mar; 50(3):630-636.
-
Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. J Infect Dis. 2021 10 28; 224(8):1410-1421.
-
Budamagunta V, Manohar-Sindhu S, Yang Y, He Y, Traktuev DO, Foster TC, Zhou D. Senescence-associated hyper-activation to inflammatory stimuli in vitro. Aging (Albany NY). 2021 08 10; 13(15):19088-19107.
-
Antwi-Amoabeng D, Ghuman J, Ghuman J, Beutler BD, Ulanja MB, Kuriakose K, Bowman A. Ponatinib-associated panniculitis: Case report and review of the literature. Cancer Treat Res Commun. 2021; 27:100357.
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021 05; 29(5):654-666.
-
H?lzl-Armstrong L, N?visdal A, Cox JA, Long AS, Chepelev NL, Phillips DH, White PA, Arlt VM. In vitro mutagenicity of selected environmental carcinogens and their metabolites in MutaMouse FE1 lung epithelial cells. Mutagenesis. 2020 12 31; 35(6):453-463.
-
H?lzl-Armstrong L, Moody S, Kucab JE, Zwart EP, Bellamri M, Luijten M, Turesky RJ, Stratton MR, Arlt VM, Phillips DH. Mutagenicity of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in human TP53 knock-in (Hupki) mouse embryo fibroblasts. Food Chem Toxicol. 2021 Jan; 147:111855.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 10; 72(10):1694-1706.
-
Brusick D, Aardema MJ, Allaben WT, Kirkland DJ, Williams G, Llewellyn GC, Parker JM, Rihner MO. A weight of evidence assessment of the genotoxic potential of 4-methylimidazole as a possible mode of action for the formation of lung tumors in exposed mice. Food Chem Toxicol. 2020 Nov; 145:111652.
-
Shahid Z, Packard E, Groff A, Jain R. Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy. BMJ Case Rep. 2019 Aug 28; 12(8).
-
Moriarty O, Tu Y, Sengar AS, Salter MW, Beggs S, Walker SM. Priming of Adult Incision Response by Early-Life Injury: Neonatal Microglial Inhibition Has Persistent But Sexually Dimorphic Effects in Adult Rats. J Neurosci. 2019 04 17; 39(16):3081-3093.
-
El Chaer F, Holtzman NG, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Hardy NM, Emadi A. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. Acta Haematol. 2019; 141(2):107-110.
-
Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0(0):1-11.
-
Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957.
-
Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, Skrepnik N, Armas E, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Hochberg MC. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 10; 25(10):1598-1606.
-
Bendell JC, Joseph M, Barnes K, Mainwaring M, Shipley D, Reddy C, Blakely L, Blachly R, Lane CM, Earwood C, Kuzur M. A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer Invest. 2017 Jul 03; 35(6):386-392.
-
Lee LH, Gasilina A, Roychoudhury J, Clark J, McCormack FX, Pressey J, Grimley MS, Lorsbach R, Ali S, Bailey M, Stephens P, Ross JS, Miller VA, Nassar NN, Kumar AR. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017 02 09; 2(3):e89473.
-
Kucab JE, Hollstein M, Arlt VM, Phillips DH. Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer. 2017 02 15; 140(4):877-887.
-
Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):52-7.
-
Tripathi R, Singh P, Singh A, Chagtoo M, Khan S, Tiwari S, Agarwal G, Meeran SM, Godbole MM. Zoledronate and Molecular Iodine Cause Synergistic Cell Death in Triple Negative Breast Cancer through Endoplasmic Reticulum Stress. Nutr Cancer. 2016 May-Jun; 68(4):679-88.
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
-
Krais AM, Speksnijder EN, Melis JP, Singh R, Caldwell A, Gamboa da Costa G, Luijten M, Phillips DH, Arlt VM. Metabolic activation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and DNA adduct formation depends on p53: Studies in Trp53(+/+),Trp53(+/-) and Trp53(-/-) mice. Int J Cancer. 2016 Feb 15; 138(4):976-82.
-
Klyachkin YM, Nagareddy PR, Ye S, Wysoczynski M, Asfour A, Gao E, Sunkara M, Brandon JA, Annabathula R, Ponnapureddy R, Solanki M, Pervaiz ZH, Smyth SS, Ratajczak MZ, Morris AJ, Abdel-Latif A. Pharmacological Elevation of Circulating Bioactive Phosphosphingolipids Enhances Myocardial Recovery After Acute Infarction. Stem Cells Transl Med. 2015 Nov; 4(11):1333-43.
-
Moore CL, McClenahan SJ, Hanvey HM, Jang DS, Nelson PL, Joseph BK, Rhee SW. Beta1-adrenergic receptor-mediated dilation of rat cerebral artery requires Shaker-type KV1 channels on PSD95 scaffold. J Cereb Blood Flow Metab. 2015 Sep; 35(9):1537-46.
-
Wang Y, Frett B, McConnell N, Li HY. Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media. Org Biomol Chem. 2015 Mar 14; 13(10):2958-64.
-
Pemberton JD, MacIntosh PW, Zeglam A, Fay A. Naphazoline as a confounder in the diagnosis of carotid artery dissection. Ophthalmic Plast Reconstr Surg. 2015 Mar-Apr; 31(2):e33-5.
-
Alhusban A, Fouda AY, Ishrat T, Soliman S, Fagan SC. Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens. 2015 Jan; 33(1):170-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|